Literature DB >> 24763400

Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.

Santiago Montes-Moreno1, Ana Batlle2, Sonia González de Villambrosía3, Beatriz Sánchez-Espiridión4, Laura Cereceda4, Eva González-Barca5, Noelia Purroy6, Emilia Pardal7, Alejandro Martín8, Carlos Grande9, Francisco Mazorra10, Andrés Insunza11, Cristina Quero12, David Aguiar13, Miguel Angel Cruz14, Antonio Rueda15, Marta Llanos16, José Gómez Codina17, Francisco Ramón García Arroyo18, Dolores Caballero8, Eulogio Conde3, Andrés López6, Mariano Provencio19, Miguel Piris10.   

Abstract

Keywords:  biological classification; diffuse large B-cell lymphoma; dose-dense therapies; high-dose

Mesh：

Substances：

Year:  2014        PMID： 24763400      PMCID： PMC4116846          DOI： 10.3324/haematol.2014.104976

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  Intensified chemotherapy for diffuse large B-cell lymphomas.

Authors:  Julie M Vose
Journal:  Lancet       Date:  2011-11-26       Impact factor: 79.321

3.  A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

Authors:  Wyndham H Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; Dan Jones; Kieron Dunleavy; George Canellos; Andrew D Zelenetz; Bruce D Cheson; Eric D Hsi
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

4.  miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.

Authors:  Santiago Montes-Moreno; Nerea Martinez; Beatriz Sanchez-Espiridión; Ramon Díaz Uriarte; Maria Elena Rodriguez; Anabel Saez; Carlos Montalbán; Gonzalo Gomez; David G Pisano; Juan Fernando García; Eulogio Conde; Eva Gonzalez-Barca; Andres Lopez; Manuela Mollejo; Carlos Grande; Miguel Angel Martinez; Cherie Dunphy; Eric D Hsi; Gabrielle B Rocque; Julie Chang; Ronald S Go; Carlo Visco; Zijun Xu-Monette; Ken H Young; Miguel A Piris
Journal:  Blood       Date:  2011-06-01       Impact factor: 22.113

5.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

Authors:  René-Olivier Casasnovas; Michel Meignan; Alina Berriolo-Riedinger; Stéphane Bardet; Anne Julian; Catherine Thieblemont; Pierre Vera; Serge Bologna; Josette Brière; Jean-Philippe Jais; Corinne Haioun; Bertrand Coiffier; Franck Morschhauser
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Authors:  William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

8.  Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.

Authors:  James R Cook; Bryan Goldman; Raymond R Tubbs; Lisa Rimsza; Michael Leblanc; Patrick Stiff; Richard Fisher
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions.

Authors:  Lionel Karlin; Bertrand Coiffier
Journal:  Onco Targets Ther       Date:  2013-03-31       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.